The global ankylosing spondylitis market size is expected to reach USD 7.9 billion by 2027 registering a CAGR of 8.3%, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.
Pharmaceutical
companies are aiming at label expansion and patent extension for maintaining
their share in the market. In October 2017, Johnson & Johnson Services
received approval for Simponi Aria for AS treatment for the treatment active psoriatic
arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in
therapy area are expected to have a positive effect on the market growth.
Furthermore,
presence of favorable reimbursement policies is anticipated to propel the
growth. For instance, in Canada (Ontario) under the province’s public drug
program, Novartis AG announced the reimbursement of Cosentyx for the treatment
of ankylosing ankylosis. According to an article published by Novartis AG,
approximately 20 to 40% of patients fail to achieve sufficient clinical
improvement on anti-TNF drugs, which provides opportunities for companies to
develop novel and effective drugs.
Full Research Report On Ankylosing Spondylitis Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/ankylosing-spondylitis-market
Ankylosing
Spondylitis Market Report Highlights
- Humira was the largest
revenue-generating drug in 2019 and accounted for over 25% of the market
share due to the favorable pricing and lack of biosimilar competition
in North America
- Cosentyx is estimated to be
the fastest-growing segment due to its excellent clinical profile. In
addition, the product is patent protected for ankylosing spondylitis till
2033 in U.S. till and 2030 in Europe
- North America led the market
in 2019 due to the presence of key biopharmaceutical & pharmaceutical
companies and increased funding and research initiatives
- Key companies are adopting
strategies, such as product development, M&A, and regional expansion,
to increase their market share
- For instance, in January
2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with
3SBio Inc. to expand its product portfolio in China
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/ankylosing-spondylitis-market/request/rs1
Ankylosing
Spondylitis Market Segmentation
Grand View Research has segmented
the global ankylosing spondylitis market based on drug and region:
Ankylosing
Spondylitis Drug Outlook (Revenue, USD Million, 2016 - 2027)
- Cosentyx
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Others
Ankylosing
Spondylitis Regional Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Chile
- Columbia
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players
of Ankylosing Spondylitis Market
- AbbVie, Inc.
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Eli Lilly and Company
- UCB, Inc.
- Johnson & Johnson
Services, Inc.
- Merck & Co., Inc.
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment